Latest Breaking News On - Houng kim - Page 5 : comparemela.com

Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59) CT-P59 demonstrated neutralising capability against key emerging mutations, including SARS-CoV-2 variants first identified in New York (B.1.526), Nigeria (B.1.525) and India (B.1.617) 1 2  is ongoing; data expected in the coming months Celltrion is committed to assess the therapeutic neutralising antibodies against a wide array of emerging variants to end the pandemic May 17 2021, INCHEON, SOUTH KOREA - Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed neutralising potency against emerging variants first identified in New York (B.1.526), Nigeria (B.1.525) and India (B.1.617).

New yorkUnited statesUnited kingdomInch on gwangyoksiSouth koreaRepublic of koreaPrevention agencyCelltrion groupMarketing division at celltrion healthcareAntibody treatmentKorea disease controlHoung kimMarketing divisionபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்